Table 2.
The association between BECN1 expression with clinicopathological background.
| BECN1 immunoreactivity | |||||
|---|---|---|---|---|---|
| N | High (%) | Low (%) | p value | ||
| Total | 60 | 29 (48.3) | 31 (51.7) | ||
| Gender | Male | 34 | 17 (50.0) | 17 (50.0) | 0.7997 |
| Female | 26 | 12 (46.2) | 14 (53.8) | ||
| Age | |||||
| Median | 61 | ||||
| ≥61 | 28 | 9 (15.2) | 19 (84.8) | 0.0227 | |
| <61 | 32 | 20 (29.6) | 12 (70.4) | ||
| Histopathological grading | |||||
| Well/moderately | 48 | 23 (20.8) | 25 (79.2) | >0.05 | |
| Poorly | 12 | 6 (27.2) | 6 (81.8) | ||
| pT categories | |||||
| pT2 | 9 | 3 (33.3) | 6 (66.7) | 0.4743 | |
| pT3 | 51 | 26 (51) | 25 (49) | ||
| pN categories | |||||
| pN0/1 | 31 | 25 (80.6) | 6 (19.4) | <0.001 | |
| pN2 | 29 | 4 (13.8) | 25 (86.2) | ||
| Stage | |||||
| II | 19 | 8 (42.1) | 11 (57.9) | 0.5853 | |
| III | 41 | 21 (51.2) | 20 (48.8) | ||
| Chemosensitivity | |||||
| Sensitive | 21 | 17 (81) | 4 (19) | 0.0003 | |
| Resistant | 39 | 12 (30.8) | 27 (69.2) | ||